Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | NPEPPS | P55786 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.54 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981446 | 0.86 | KDM4E (0.71) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL6971771 | 0.85 | HTT (0.72) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL14096394 | 0.84 | PDE7A (0.77) | GAANPC1ALDH1A1LMNAKMT2A | |
| SCHEMBL2763638 | 0.84 | ALDH1A1 (0.50) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL2763637 | 0.84 | GAA (0.49) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL12889780 | 0.84 | TP53 (0.62) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL6977596 | 0.84 | KDM4E (0.73) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1548586 | 0.84 | TP53 (0.62) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL6973874 | 0.84 | TP53 (0.62) | GAANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4098385 | 0.83 | AURKA (0.56) | GAANPC1SMN1; SMN2TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107868060-B | 2- [3- (4-morpholinyl) propylamino ] -3-aryl-4-quinolinone compounds and application thereof | 沈阳药科大学 | 2021-04-09 | — | — | CN | disclosed |
| CN-107793369-B | 2- [2- (2-methoxyphenoxy) ethylamino ] -3-aryl-4-quinazolinone compound and application thereof | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2019-12-10 | — | — | CN | disclosed |
| US-20100305121-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-12-02 | — | — | US | disclosed |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070203236-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | UNITED STATES GOVERNMENT | 2007-08-30 | — | — | US | disclosed |
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
| EP-0653423-B1 | Process for the preparation of substituted quinazoline-2,4-diones | CLARIANT GMBH (DE) | 1999-06-16 | — | — | EP | disclosed |
| US-5539114-A | Process for the preparation of substituted quinazoline-2,4,-diones | HOECHST AG (DE) | 1996-07-23 | — | — | US | disclosed |
| EP-0653423-A1 | Process for the preparation of substituted quinazoline-2,4-diones | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203236-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | FADS2, ACOT7, FADS1 | GAA 812/4885NPC1 778/4885SMN1; SMN2 4263/4885 |
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | GAA 638/4885NPC1 716/4885SMN1; SMN2 2735/4885 |
| US-20070208045-A1 | SUBSTITUTED-(QUINAZOLINYL)PHENYL THIOPHENYL-SULFONYLUREAS, METHODS FOR MAKING AND INTERMEDIATES THEREOF | P2RY4, P2RY6, P2RY13 | GAA 893/4885NPC1 2207/4885SMN1; SMN2 3005/4885 |
| US-20100305121-A1 | NOVEL ANTAGONISTS OF THE HUMAN FATTY ACID SYNTHASE THIOESTERASE | FADS2, ACOT7, FADS1 | GAA 812/4885NPC1 778/4885SMN1; SMN2 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.